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A B S T R A C T
Infections in patients with cirrhosis are common among those who develop variceal hemorrhage.
Prophylactic antimicrobial treatment with third generation cephalosporins is recommended in patients
with advanced cirrhosis and gastrointestinal hemorrhage. However no infectious source is identiﬁed in
up to 50% of patients with cirrhosis and clinical sepsis. We report the ﬁrst case of Paracoccus yeeii
bacteremia in a patient with decompensated cirrhosis who presented with variceal hemorrhage. This
rare gram negative organism that occurs naturally in the soil has been difﬁcult to isolate until recent
technological advances and may not be susceptible to third generation cephalosporins. Our case
reinforces the challenges in isolating rare infections in patients with cirrhosis, the need to consider
uncommon organisms in infected but culture negative patients with cirrhosis, and the importance of
optimizing antimicrobials to reduce the incidence of drug resistant organisms.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Infections are common in patients with cirrhosis and have been
found in up to 66% of patients with variceal hemorrhage [1].
Prophylactic treatment with third generation cephalosporins is
recommended in patients with advanced cirrhosis and gastroin-
testinal bleeding to cover for the predominant causative gut ﬂora
organisms [2,3]. Treatment is recommended even if no causative
organism is identiﬁed as up to 50% of patients with cirrhosis and
clinical sepsis have negative cultures [4]. Identifying appropriate
antimicrobials can be challenging without a causative organism,
and the empiric use of broad spectrum antimicrobials contributes
to multidrug resistant organisms. We report the ﬁrst known case of
Paracoccus yeeii bacteremia in a patient with decompensated
cirrhosis who presented with variceal hemorrhage. This rare gram
negative organism may not be susceptible to third generation
cephalosporins. This ﬁnding may have implications for the
management of infected but culture negative patients with
cirrhosis.* Corresponding author.
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A 42 year old gentleman with decompensated cirrhosis from
genotype 1a (G1a) hepatitis C (HCV) had been treated with
24 weeks of ledipasvir and sofosbuvir which ended 4.5 months
earlier. He had been recently treated with ciproﬂoxacin for
Klebsiella pneumoniae bacteremia of unknown source. His comor-
bidities included proliferative glomerulonephritis and chronic
lymphedema. The patient presented with new onset jaundice
(total bilirubin 23 mg/dL, direct bilirubin 18 mg/dL, alkaline
phosphatase 99 U/L, alanine aminotransferase 31 U/L, aspartate
aminotransferase 86 U/L) that peaked to total bilirubin 44 mg/dL
and direct bilirubin 31 mg/dL. Model for End-Stage Liver Disease
(MELD) score on admission was 27. Given the report of subjective
fevers in the setting of recently treated K. pneumoniae bacteremia
of unknown source, admission blood and urine cultures were
obtained but were without growth. Diagnostic paracentesis was
attempted but the patient had minimal ascites. Molecular studies
revealed HCV relapse (HCV viral load = 4.44 log IU/mL) without
NS5b resistance (insufﬁcient sample for NS5a) and undetectable
hepatitis B (HBV) and adenovirus. There was no serologic evidence
of acute infection with hepatitis E, cytomegalovirus (CMV), or
Epstein Barr virus (EBV). Liver biopsy demonstrated cirrhosis with
moderate chronic inﬂammation, focal severe neutrophilic inﬁl-
trates with cholestasis, and ductular proliferation. Magneticder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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creatography (MRCP) showed no cholangitis or abscess. Although
drug induced liver injury from ciproﬂoxacin was clinically
suspected, two sets of blood cultures were obtained daily due to
concern for infection and lack of clinical improvement.
The patient elected discharge but was readmitted within 24
hours with hematemesis from variceal hemorrhage and portal
hypertensive gastropathy. Empiric treatment for undifferentiated
septic shock including spontaneous bacterial peritonitis prophy-
laxis were ceftriaxone 2 g IV every 24 hours, metronidazole 500 mg
IV every 8 hours, and vancomycin 2 g IV every 12 hours. Diagnostic
paracentesis was again attempted but the patient had minimal
ascites. Given the lack of clinical improvement and the ﬁnding of
bowel edema and severe colitis on computer tomography,
infectious disease was consulted. It was recommended to adjust
antimicrobials to piperacillin-tazobactam 3.375 mg every 6 hours,
metronidazole 500 mg IV every 8 hours, and vancomycin 125 mg
PO every 6 hours to cover for gut ﬂora including Clostridium difﬁcile
until it could be ruled out.
Blood cultures collected the day before discharge of the
previous admission ﬂagged as “positive” after 5 days of incubation
in the aerobic bottle (BacTec Plus Aerobic/F), but no organisms
were seen upon Gram stain. However, after two days of incubation,
small mucoid colonies of oxidase positive Gram negative
coccobacilli were seen growing on Chocolate agar only. The team
was notiﬁed and antimicrobials were adjusted to only piperacillin-
tazobactam 4.5 g every 6 hours. The organism was very slow
growing, and initial attempts at identiﬁcation were unsuccessful.
After an additional two days of incubation, an identiﬁcation of
Paracoccus yeeii was made by Matrix Assisted Laser Desorption
Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS;
Vitek MS) with a match of 99.9% to the Vitek MS IVD unclaimed
database. Identiﬁcation was conﬁrmed by sequencing of the ﬁrst
500 bp of the 16S gene. Upon speciation, the patient was switched
to ceftazidime 1 g every 12 hours to cover for P. yeeii as well as
concern for a hospital acquired pneumonia. The patient completed
a 2 week treatment course of gram negative antimicrobial coverage
with two beta lactam agents and had clinical improvement with no
other culture growth of P. yeeii. Unfortunately, the patient
developed end-stage liver disease and eventually succumbed to
death due to septic shock from Citrobacter freundii pneumonia.
Discussion
To our knowledge, this is the ﬁrst reported case of P. yeeii in a
patient with cirrhosis. Patients with decompensated cirrhosis are
at high risk of infection from immune dysregulation, a heightened
inﬂammatory response, altered gut ﬂora, and bowel translocation.
However, no causative organism is found in up to 50% of patients
with decompensated cirrhosis presenting with clinical sepsis. This
case of bacteremia with a rare gram negative organism is
instructive regarding optimal diagnosis and treatment of infection
in patients with decompensated cirrhosis who have an unclear
source of infection as they have an extremely high risk of morbidity
and mortality.
P. yeeii is an aerobic gram negative coccobacillus that has been
isolated in soil and marine sediment, and has been rarely reported
as infections in humans. P. yeeii has been identiﬁed in the past
through commonly available biochemical tests, and this case
demonstrates the utility of MALDI-TOF MS for the identiﬁcation of
this infrequently encountered organism [5,6]. The few reported
cases of P. yeeii to date have entailed peritonitis among peritoneal
dialysis patients [5,7], myocarditis in a heart transplant patient [8],
corneal graft infection [9], and heart failure with bullous skinlesions [10]. All cases identiﬁed P. yeeii through culture of affected
tissues. Only 2 cases, including ours, have been associated with
bacteremia and ours is the ﬁrst case of a patient with cirrhosis. The
source of bacteremia in our case remains unclear, but it is plausible
that the patient’s lymphedema and bowel edema could be sources
for this environmentally found organism. Over the previous year,
the patient had several episodes of bacteremia thought to be from
bowel translocation including Group G b-hemolytic streptococci,
Streptococcus mitis/oralis,Citrobacter braakii, and Enterococcus
faecium (the patient was not on chronic antimicrobials). The
challenges in isolating P. yeeii suggest that it is underdiagnosed.
MALDI-TOF may help with rapid diagnosis and guide appropriate
treatment when initial cultures in patients with decompensated
cirrhosis and clinical sepsis are negative.
It is recommended that patients with advanced cirrhosis who
develop gastrointestinal bleeding be treated empirically with third
generation cephalosporins [2,4]. However, this case illustrates that
uncommon gram negative organisms may not necessarily be
covered with third generation cephalosporins. Although we did
not have antimicrobial susceptibilities performed in our case, the
existing literature on P. yeeii suggests that the organism is
susceptible to ﬂuoroquinolones and beta-lactams though higher
minimum inhibitory concentrations (MICs) were reported with
third generation cephalosporins [5].
This case reinforces the challenges in isolating rare infections in
patients with cirrhosis. In the absence of obvious infectious
sources in a patient with decompensated cirrhosis, consideration
should be given to uncommon gram negative organisms.
Collaboration with infectious disease specialists and microbiolo-
gists is warranted in these cases to isolate infectious organisms and
to identify appropriate antimicrobials promptly.
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